Bajaj Healthcare Limited announced its audited financial results for the quarter and year ended March 31, 2026, during its board meeting on May 08, 2026. The company reported a total income of ₹15,601.37 lakhs for the quarter ended March 31, 2026, compared to ₹16,286.98 lakhs in the previous quarter and ₹16,804.41 lakhs in the corresponding quarter of the previous year. Net profit after tax for the current quarter stood at a loss of ₹2,285.06 lakhs, following a profit of ₹1,567.38 lakhs in the preceding quarter and ₹1,117.78 lakhs in the same quarter last year. This significant decrease was largely due to a one-time exceptional item reversal of income amounting to ₹3,324.66 lakhs related to technical know-how arrangements.

Bajaj Healthcare Limited is a pharmaceutical company involved in the manufacture of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage formulations. The company operates in a single reportable segment, Pharmaceuticals, and serves both domestic and international markets. During the 2025-26 period, the company expanded its portfolio by acquiring Genix Pharmaceuticals Private Limited in April 2025 to bolster its manufacturing capabilities. Additionally, the board recommended a final dividend of 30% (₹1.50 per share) for the financial year 2025-26, reflecting continued commitment to shareholder returns despite the quarterly loss.